Relative Tumour Volume in Canine Oral Melanoma Staging and Prognosis.
dog
oral melanoma
prognosis
relative tumour volume
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
revised:
05
09
2024
received:
22
02
2024
accepted:
19
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
11
10
2024
Statut:
aheadofprint
Résumé
Melanoma is one of the most common canine oral malignant tumours and is highly aggressive and metastatic, even at the early stages of development. Surgery relies on wide excision of the primary tumour and regional lymphadenectomy, with or without adjuvant therapy. Tumour location and size are important when considering staging, which ultimately affects the curative intent of surgery. Nevertheless, absolute tumour volume (TV) is not related to the vast phenotypic variability within canine breeds. This study aimed to determine the cutoff values of two ratios-tumour-to-head volume (THR) and tumour-to-body volume (TBR)-and assess whether they could be associated with the odds of finding metastasis at presentation and/or the likelihood of achieving tumour-free excision margins. A retrospective case series involving 51 dogs was used to evaluate the preoperative head/neck and chest computed tomography and histopathology of the primary mass and excised lymph nodes. Higher TV, THR% and TBR% values were associated with bone lysis and mitotic count (MC). The Ki67 index was significantly associated with local and distant metastases at presentation, whereas MC was associated with local metastasis alone. Tumour-infiltrated surgical margins were associated with caudally located tumours, regardless of the tumour size. Dogs with lymph node metastasis at presentation were seven times more prone to have local relapse. TV, THR% and TBR% values were positively associated with local lymph node metastasis at presentation. Cutoff values for both TV and TBR% were proposed to predict lymph node metastasis at presentation (TV = 6.423 cm
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação para a Ciência e a Tecnologia
Organisme : Centro de Investigação Interdisciplinar de Sanidade Animal (CIISA)
Organisme : AL4AnimalS
Organisme : Universidade de Lisboa
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
P. J. Bergman, “Canine oral melanoma,” Clinical Techniques in Small Animal Practice 22, no. 2 (2007): 55–60.
L. B. Brønden, S. S. Nielsen, N. Toft, and A. T. Kristensen, “Data From the Danish Veterinary Cancer Registry on the Occurrence and Distribution of Neoplasms in Dogs in Denmark,” Veterinary Record 166, no. 19 (2010): 586–590.
M. Mikiewicz, K. Paździor‐Czapula, M. Gesek, V. Lemishevskyi, and I. Otrocka‐Domagała, “Canine and Feline Oral Cavity Tumours and Tumour‐Like Lesions: A Retrospective Study of 486 Cases (2015–2017),” Journal of Comparative Pathology 172 (2019): 80–87.
A. M. Razmara, L. A. Wittenburg, S. Al‐Nadaf, et al., “Prevalence and Clinicopathologic Features of Canine Metastatic Melanoma Involving the Central Nervous System: A Retrospective Analysis and Comparative Review,” Frontiers in Oncology 12 (2022): 1–11.
W. T. N. Culp, N. Ehrhart, S. J. Withrow, et al., “Results of Surgical Excision and Evaluation of Factors Associated With Survival Time in Dogs With Lingual Neoplasia: 97 Cases (1995–2008),” Journal of the American Veterinary Medical Association 242, no. 10 (2013): 1392–1397.
J. L. Tuohy, L. E. Selmic, M. Bv, et al., “Outcome Following Curative‐Intent Surgery for Oral Melanoma in Dogs,” Journal of the American Veterinary Medical Association 245, no. 11 (2014): 1266–1273.
K. Green and S. E. Boston, “Bilateral Removal of the Mandibular and Medial Retropharyngeal Lymph Nodes Through a Single Ventral Midline Incision for Staging of Head and Neck Cancers in Dogs: A Description of Surgical Technique,” Veterinary and Comparative Oncology 15, no. 1 (2017): 208–214.
D. Giacobino, M. Camerino, F. Riccardo, et al., “Difference in Outcome Between Curative Intent vs Marginal Excision as a First Treatment in Dogs With Oral Malignant Melanoma and the Impact of Adjuvant CSPG4‐DNA Electrovaccination: A Retrospective Study on 155 Cases,” Veterinary and Comparative Oncology 19, no. 4 (2021): 651–660.
M. L. Raleigh, M. M. Smith, and K. Taney, “Curative Intent Surgery of Oral Malignant Melanoma and Regional Lymph Node Biopsy Assessment in 25 Dogs: 2006‐2017,” Journal of Veterinary Dentistry 38, no. 4 (2021): 193–198.
S. Murphy, A. M. Hayes, L. Blackwood, G. Maglennon, H. Pattinson, and A. H. Sparkes, “Oral Malignant Melanoma—The Effect of Coarse Fractionation Radiotherapy Alone or With Adjuvant Carboplatin Therapy,” Veterinary and Comparative Oncology 3, no. 4 (2005): 222–229.
S. E. Boston, X. Lu, W. T. N. Culp, et al., “Efficacy of Systemic Adjuvant Therapies Administered to Dogs After Excision of Oral Malignant Melanomas: 151 Cases (2001–2012),” Journal of the American Veterinary Medical Association 245, no. 4 (2014): 401–407.
M. Kawabe, T. Mori, Y. Ito, et al., “Outcomes of Dogs Undergoing Radiotherapy for Treatment of Oral Malignant Melanoma,” Journal of the American Veterinary Medical Association 247, no. 10 (2015): 1146–1153.
S. Cancedda, C. Rohrer Bley, L. Aresu, et al., “Efficacy and Side Effects of Radiation Therapy in Comparison With Radiation Therapy and Temozolomide in the Treatment of Measurable Canine Malignant Melanoma,” Veterinary and Comparative Oncology 14, no. 4 (2016): e146–e157.
E. Treggiari, J. P. Grant, and S. M. North, “A Retrospective Review of Outcome and Survival Following Surgery and Adjuvant Xenogeneic DNA Vaccination in 32 Dogs With Oral Malignant Melanoma,” Journal of Veterinary Medical Science 78, no. 5 (2016): 845–850.
L. A. Piras, F. Riccardo, S. Iussich, et al., “Prolongation of Survival of Dogs With Oral Malignant Melanoma Treated by En Bloc Surgical Resection and Adjuvant CSPG4‐Antigen Electrovaccination,” Veterinary and Comparative Oncology 15, no. 3 (2017): 996–1013.
F. Riccardo, L. Tarone, M. Camerino, et al., “Antigen Mimicry as an Effective Strategy to Induce CSPG4‐Targeted Immunity in Dogs With Oral Melanoma: A Veterinary Trial,” Journal for Immunotherapy of Cancer 10, no. 5 (2022): 1–16.
F. J. M. Verstraete, “Mandibulectomy and Maxillectomy,” Veterinary Clinics: Small Animal Practice 35, no. 4 (2005): 1009–1039.
P. J. Bergman, “Melanoma review,” VCA Animal Hospitals. (2005): 1–17.
M. Camerino, D. Giacobino, L. Manassero, et al., “Prognostic Impact of Bone Invasion in Canine Oral Malignant Melanoma Treated by Surgery and Anti‐CSPG4 Vaccination: A Retrospective Study on 68 Cases (2010–2020),” Veterinary and Comparative Oncology 20, no. 1 (2022): 189–197.
S. H. Smith, M. H. Goldschmidt, and P. M. Mcmanus, “A Comparative Review of Melanocytic Neoplasms,” Veterinary Pathology 39, no. 6 (2002): 651–678.
K. P. Freeman, K. A. Hahn, F. D. Harris, and G. K. King, “Treatment of Dogs With Oral Melanoma by Hypofractionated Radiation Therapy and Platinum‐Based Chemotherapy (1987–1997),” Journal of Veterinary Internal Medicine 17, no. 1 (2003): 96–101.
R. C. Smedley, W. L. Spangler, D. G. Esplin, et al., “Prognostic Markers for Canine Melanocytic Neoplasms: A Comparative Review of the Literature and Goals for Future Investigation,” Veterinary Pathology 48, no. 1 (2011): 54–72.
L. Owen, “TNM Classification of Tumours in Domestic Animals,” World Heal Organ (1980): 1–52. (VPH/CMO/80.20), http://www.cabdirect.org/abstracts/19812266568.html.
K. A. Carroll, C. A. Kuntz, J. Heller, A. Peters, R. Rotne, and A. Dunn, “Tumor Size as Predictor of Lymphatic Invasion in Canine Melanomas,” Journal of the American Veterinary Medical Association 256, no. 10 (2020): 1123–1128.
R. C. Smedley, L. Bongiovanni, C. Bacmeister, et al., “Diagnosis and Histopathologic Prognostication of Canine Melanocytic Neoplasms: A Consensus of the Oncology‐Pathology Working Group,” Veterinary and Comparative Oncology 20, no. 4 (2022): 739–751.
D. Dejaco, C. Url, V. H. Schartinger, et al., “Approximation of Head and Neck Cancer Volumes in Contrast Enhanced CT,” Cancer Imaging 15, no. 1 (2015): 1–9.
C. Le Fèvre, R. Sun, H. Cebula, et al., “Ellipsoid Calculations Versus Manual Tumor Delineations for Glioblastoma Tumor Volume Evaluation,” Scientific Reports 12, no. 1 (2022): 1–9.
S. B. Heymsfield, J. Wang, J. Kehayias, S. Heshka, S. Lichtman, and R. N. Pierson, “Chemical Determination of Human Body Density In Vivo: Relevance to Hydrodensitometry,” American Journal of Clinical Nutrition 50, no. 6 (1989): 1282–1289.
E. Ferreira, A. C. Bertagnolli, M. F. Cavalcanti, F. C. Schmitt, and G. D. Cassali, “The Relationship Between Tumour Size and Expression of Prognostic Markers in Benign and Malignant Canine Mammary Tumours,” Veterinary and Comparative Oncology 7, no. 4 (2009): 230–235.
S. Flukes, S. Lohia, C. A. Barker, et al., “Primary Tumor Volume as a Predictor of Distant Metastases and Survival in Patients With Sinonasal Mucosal Melanoma,” Head & Neck 42, no. 11 (2020): 3316–3325.
F. Czichon, C. R. Bley, and V. Meier, “Relative Tumor Volume Has Prognostic Relevance in Canine Sinonasal Tumors Treated With Radiation Therapy: A Retrospective Study,” PLoS One 17 (2022): e0269083.
J. A. Ramos‐Vara, M. E. Beissenherz, M. A. Miller, et al., “Retrospective Study of 338 Canine Oral Melanomas With Clinical, Histologic, and Immunohistochemical Review of 129 Cases,” Veterinary Pathology 37, no. 6 (2000): 597–608.
K. Grüntzig, R. Graf, G. Boo, et al., “Swiss Canine Cancer Registry 1955–2008: Occurrence of the Most Common Tumour Diagnoses and Influence of Age, Breed, Body Size, Sex and Neutering Status on Tumour Development,” Journal of Comparative Pathology 155, no. 2–3 (2016): 156–170.
L. E. Williams and R. A. Packer, “Association Between Lymph Node Size and Metastasis in Dogs With Oral Malignant Melanoma: 100 Cases (1987–2001),” Journal of the American Veterinary Medical Association 222, no. 9 (2003): 1234–1236.
A. T. Nishiya, C. O. Massoco, C. R. Felizzola, et al., “Comparative Aspects of Canine Melanoma,” Veterinary sciences 3, no. 1 (2016): 1–22.
J. A. Grimes, L. A. Mestrinho, J. Berg, et al., “Histologic Evaluation of Mandibular and Medial Retropharyngeal Lymph Nodes During Staging of Oral Malignant Melanoma and Squamous Cell Carcinoma in Dogs,” Journal of the American Veterinary Medical Association 254, no. 8 (2019): 938–943.
A. F. Delgado and A. F. Delgado, “Complete Lymph Node Dissection in Melanoma: A Systematic Review and Meta‐Analysis,” Anticancer Research 37, no. 12 (2017): 6825–6829.
T. K. Yoo, B. J. Kang, S. H. Kim, et al., “Axillary Lymph Node Dissection Is Not Obligatory in Breast Cancer Patients With Biopsy‐Proven Axillary Lymph Node Metastasis,” Breast Cancer Research and Treatment 181, no. 2 (2020): 403–409.
F. Mulita, S. Lotfollahzadeh, and S. K. R. Mukkamalla, Lymph Node Dissection (Treasure Island, FL: StatPearls Publishing, 2023).
Z. H. Hopkins, R. P. Carlisle, Z. E. Frost, et al., “Risk Factors and Predictors of Survival Among Patients With Amelanotic Melanoma Compared to Melanotic Melanoma in the National Cancer Database,” Journal of Clinical and Aesthetic Dermatology 11, no. 12 (2013): 63.
I. L. Bergin, R. C. Smedley, D. G. Esplin, W. L. Spangler, and M. Kiupel, “Prognostic Evaluation of ki67 Threshold Value in Canine Oral Melanoma,” Veterinary Pathology 48, no. 1 (2011): 41–53.
X. Ma, Y. Wu, T. Zhang, et al., “Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients Without Distant Metastases,” Journal of Cancer 8, no. 18 (2017): 3828–3837.
T. Laver, B. R. Feldhaeusser, C. S. Robat, et al., “Post‐Surgical Outcome and Prognostic Factors in Canine Malignant Melanomas of the Haired Skin: 87 Cases (2003–2015),” Canadian Veterinary Journal 59, no. 9 (2018): 981–987.
Q. Liu, Z. Peng, L. Shen, and L. Shen, “Prognostic and Clinicopathological Value of Ki‐67 in Melanoma: A Meta‐Analysis,” Frontiers in Oncology 11 (2021): 1–8.
M. S. Khan, T. V. Luong, J. Watkins, C. Toumpanakis, M. E. Caplin, and T. Meyer, “A Comparison of Ki‐67 and Mitotic Count as Prognostic Markers for Metastatic Pancreatic and Midgut Neuroendocrine Neoplasms,” British Journal of Cancer 108, no. 9 (2013): 1838–1845.
L. Rossi, E. Laas, P. Mallon, et al., “Prognostic Impact of Discrepant Ki67 and Mitotic Index on Hormone Receptor‐Positive, HER2‐Negative Breast Carcinoma,” British Journal of Cancer 113, no. 7 (2015): 996–1002.
H. M. Ragab, N. Samy, M. Afify, N. A. El Maksoud, and H. A. M. Shaaban, “Assessment of Ki‐67 as a Potential Biomarker in Patients With Breast Cancer,” Journal, Genetic Engineering & Biotechnology 16, no. 2 (2018): 479–484.
B. Brunetti, B. Bacci, C. Angeli, C. Benazzi, and L. V. Muscatello, “p53, ER, and Ki67 Expression in Canine Mammary Carcinomas and Correlation With Pathological Variables and Prognosis,” Veterinary Pathology 58, no. 2 (2021): 325–331.
A. M. Burke, M. Carrasquilla, W. C. Jean, et al., “Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy,” Frontiers in Oncology 11 (2022): 1–6.
B. N. Sarowitz, G. J. Davis, and S. Kim, “Outcome and Prognostic Factors Following Curative‐Intent Surgery for Oral Tumours in Dogs: 234 Cases (2004 to 2014),” Journal of Small Animal Practice 58, no. 3 (2017): 146–153.